Tuesday, May 25, 2021

UI Pharmaceuticals recently contracted with G1 Therapeutics (Next Generation Cancer Therapies) by manufacturing clinical drug supplies of an investigational drug therapy product called COSELA™.  G1 Therapeutics announced that the U.S. Food and Drug Administration (FDA) approved COSELA™ (trilaciclib) for injection - the first and only therapy designed to help protect bone marrow (myeloprotection) against extensive-stage small cell lung cancer (ES-SCLC) when administered prior to treatment.  COSELA™ became commercially available in the spring of 2021.  More about COSELA™.

About UI Pharmaceuticals:

UI Pharmaceuticals is the largest and most experienced university-affiliated FDA-registered pharmaceutical manufacturing facility in the United States that produces both sterile and non-sterile dosage forms.  UI Pharmaceuticals has been developing formulations, manufacturing products, and conducting analytical testing for almost 45 years.